AngioDynamics Enters Material Agreement, Incurs Financial Obligation
Ticker: ANGO · Form: 8-K · Filed: May 28, 2025 · CIK: 1275187
| Field | Detail |
|---|---|
| Company | Angiodynamics Inc (ANGO) |
| Form Type | 8-K |
| Filed Date | May 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation
Related Tickers: ANGI
TL;DR
ANGI just signed a big deal and took on debt. Watch this space.
AI Summary
On May 28, 2025, AngioDynamics, Inc. filed an 8-K report detailing a material definitive agreement and a direct financial obligation. The filing indicates the company entered into a new agreement and incurred a financial obligation, though specific details of the agreement and obligation are not provided in this excerpt.
Why It Matters
This filing signals a significant new financial commitment or partnership for AngioDynamics, which could impact its future operations and financial health.
Risk Assessment
Risk Level: medium — Entering into material agreements and financial obligations inherently carries risks related to performance, repayment, and market conditions.
Key Players & Entities
- AngioDynamics, Inc. (company) — Registrant
- May 28, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 14 Plaza Drive, Latham, New York 12110 (address) — Principal Executive Offices
- 518-795-1400 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by AngioDynamics?
The filing states that AngioDynamics entered into a material definitive agreement, but the specific terms and nature of this agreement are not detailed in the provided excerpt.
What is the specific financial obligation incurred by AngioDynamics?
The 8-K filing indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, but the details of this obligation are not specified in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on May 28, 2025.
What is AngioDynamics' principal executive office address?
AngioDynamics' principal executive office is located at 14 Plaza Drive, Latham, New York 12110.
What is AngioDynamics' telephone number?
AngioDynamics' telephone number is (518) 795-1400.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 28, 2025 regarding ANGIODYNAMICS INC (ANGO).